Wednesday 02 April 2025
Internal Reference Number: FOI_8388
Date Request Received: 17/01/2025 00:00:00
Date Request Replied To: 05/02/2025 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Researcher
| Question Number 1: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2024: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis • Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) | |
| Answer To Question 1: • Aflibercept 1069 • Bevacizumab 8 • Brolucizumab 0 • Dexamethasone 12 • Faricimab 929 • Fluocinolone acetonide 0 • Ranibizumab - Lucentis 5 • Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) 0 | |
| Question Number 2: Please see attached | |
| Answer To Question 2: Please see attached. To accompany this answer to question 2 please also see the documents listed below:  FOI 8388 - Q2 - intra-vitreal injections or implants -Completed.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
